FR2809621B1 - Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques - Google Patents

Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques

Info

Publication number
FR2809621B1
FR2809621B1 FR0006178A FR0006178A FR2809621B1 FR 2809621 B1 FR2809621 B1 FR 2809621B1 FR 0006178 A FR0006178 A FR 0006178A FR 0006178 A FR0006178 A FR 0006178A FR 2809621 B1 FR2809621 B1 FR 2809621B1
Authority
FR
France
Prior art keywords
antidiarrhoists
preparation
receptor antagonist
cannabinoid receptor
central cannabinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0006178A
Other languages
English (en)
Other versions
FR2809621A1 (fr
Inventor
Tiziano Croci
Luciano Manara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Priority to FR0006178A priority Critical patent/FR2809621B1/fr
Priority to AU2001260406A priority patent/AU2001260406A1/en
Priority to PCT/FR2001/001432 priority patent/WO2001085092A2/fr
Publication of FR2809621A1 publication Critical patent/FR2809621A1/fr
Application granted granted Critical
Publication of FR2809621B1 publication Critical patent/FR2809621B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0006178A 2000-05-12 2000-05-12 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques Expired - Fee Related FR2809621B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR0006178A FR2809621B1 (fr) 2000-05-12 2000-05-12 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques
AU2001260406A AU2001260406A1 (en) 2000-05-12 2001-05-11 Antidiarrheal cannabinoid cb-1 receptor antagonist
PCT/FR2001/001432 WO2001085092A2 (fr) 2000-05-12 2001-05-11 Antagoniste des recepteurs aux cannabinoides cb-1 antidiarrheique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0006178A FR2809621B1 (fr) 2000-05-12 2000-05-12 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques

Publications (2)

Publication Number Publication Date
FR2809621A1 FR2809621A1 (fr) 2001-12-07
FR2809621B1 true FR2809621B1 (fr) 2002-09-06

Family

ID=8850242

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0006178A Expired - Fee Related FR2809621B1 (fr) 2000-05-12 2000-05-12 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques

Country Status (3)

Country Link
AU (1) AU2001260406A1 (fr)
FR (1) FR2809621B1 (fr)
WO (1) WO2001085092A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US7423067B2 (en) 2002-03-26 2008-09-09 Merck & Co., Inc. Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
CA2479744A1 (fr) 2002-03-28 2003-10-09 Paul E. Finke 2,3-diphenyl-pyridines substituees
JP4459629B2 (ja) 2002-04-12 2010-04-28 メルク エンド カムパニー インコーポレーテッド 二環式アミド
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
MXPA05007114A (es) * 2003-01-02 2005-08-26 Hoffmann La Roche Nuevos agonistas inversos del receptor cb1.
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1574211A1 (fr) 2004-03-09 2005-09-14 Inserm Utilisation d'antagonistes des récepteurs CB1 pour la fabrication d'un médicament destiné au traitement des maladies hépatiques
WO2006025069A2 (fr) 2004-07-12 2006-03-09 Cadila Healthcare Limited Nouveaux composes heterocycliques
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
WO2007039797A1 (fr) * 2005-10-03 2007-04-12 Pfizer Products Inc. Utilisation d'antagonistes du recepteur cannabinoide de type 1 pour traiter les inflammations et l'arthrite

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
FR2809621A1 (fr) 2001-12-07
AU2001260406A1 (en) 2001-11-20
WO2001085092A3 (fr) 2002-08-29
WO2001085092A2 (fr) 2001-11-15

Similar Documents

Publication Publication Date Title
FR2758723B1 (fr) Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2799124B1 (fr) Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2804288B1 (fr) Ensemble d'adaptation pour casque
FR2804683B1 (fr) Monoacylarylphosphines organometalliques, leur preparation et leur utilisation pour la preparation d'acylphosphines asymetriques utiles comme photoamorceurs
FR2804959B1 (fr) Utilisation de derives de paullones pour la fabrication de medicaments
DZ3347A1 (fr) Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase
LU92397I2 (fr) Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable
HUP0302044A3 (en) Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
FR2816908B1 (fr) Unite d'embrayage
HUP0203681A3 (en) Pharmaceutical compositions containing agonists specific for the peripheral cannabinoid receptor and their use
FR2827758B1 (fr) Ancillaire pour systeme d'ostheosynthese rachidienne
AU2001250205A1 (en) Prostaglandin d2 receptor antagonists
EP1229910A4 (fr) Antagonistes des recepteurs d'integrine
EP1534823A4 (fr) Utilisation d'agents de liaison isocyanate pour produire des conjugues biopolymere-substance active hydrolysables
EP1470357A4 (fr) Bride pour raccordement d'elements tubulaires
EP1154316A4 (fr) Unite de presentation d'images a retroprojection
AU2001260406A1 (en) Antidiarrheal cannabinoid cb-1 receptor antagonist
EP1141240A4 (fr) Utilisation de l'accouplement de cd40 pour modifier l'usage du recepteur des lymphocytes t
FR2832587B1 (fr) Systeme de reperage et d'adressage des feux d'un reseau de balisage
FR2811998B1 (fr) Utilisation d'heteroxylanes pour la preparation de compositions filmogenes
FR2723317B1 (fr) Utilisation d'antagonistes de la neurotensine pour la preparation de medicaments diuretiques
FR2758460B1 (fr) Utilisation des agonistes des recepteurs beta-3 adrenergiques pour la preparation de medicaments cicatrisants
FR2828403B1 (fr) Utilisation de molecules solubles hla de classe 1 pour la preparation de compositions pharmaceutiques utiles pour inhiber l'angiogenese
EP1395593A4 (fr) Nouveaux derives de pyrazolopyrimidinethione, procedes de preparation de ceux-ci et utilisation comme agents therapeutiques pour les dysfonctionnements de l'erection
HUP9902674A2 (en) Use of estrogen agonists/antagonists as a medicament

Legal Events

Date Code Title Description
ST Notification of lapse